Abemaciclib clinical trials

J1S-MC-JP04: A Randomized, Open-Label Phase 2 Study Evaluating Abemaciclib in Combination with Irinotecan and Temozolomide in Participants with Relapsed or Refractory Ewing’s Sarcoma

This study is looking at a new way to treat Ewing's sarcoma that has come back or hasn’t responded to previous treatments. It uses a tablet called Verzenios (abemaciclib) along with two chemotherapy drugs, irinotecan and temozolomide. Researchers want to see how well this combination stops the cancer from growing.

I3Y-MC-JPCS: A Phase 1b/2 Study of Abemaciclib in Combination with Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination with Temozolomide (Part B) in Pediatric and Young Adult Patients with Relapsed/Refractory Solid Tumors and Abemaciclib in Combination with Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients with Relapsed/Refractory Neuroblastoma (Part C).

This study is testing a new medicine, abemaciclib, combined with other treatments for children and young adults with solid cancers that have come back or not responded to previous treatment. Researchers want to find the safest and most effective dose.

A randomized, 2-arm, open-label, phase II study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant) with or without a short course of induction chemotherapy with paclitaxel as first-line therapy in patients with unresectable locally advanced or metastatic HR-positive/HER2-negative breast cancer with aggressive disease criteria. (ABIGAIL)

This study looks at new ways to treat advanced breast cancer that's hormone-sensitive. It tests if adding a short course of chemotherapy to existing hormone treatments can help shrink tumours more effectively.

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

This study is testing a new medicine called EP0062 for advanced breast cancer. It aims to find the safest and most effective dose, both alone and with other standard treatments, for women whose cancer has specific features.

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

This study looks at a new drug, AZD8421, for advanced breast cancer (ER+ HER2- type) and a type of ovarian cancer. It checks how safe and effective it is, sometimes alone and sometimes with other cancer medicines.

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

This study looks at new drug combinations (Elacestrant and Abemaciclib) for people with breast cancer that has spread to the brain. It aims to find the right dose and see how well the new combination works for ER-positive, HER-2 negative breast cancer.

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

This study is looking at a new drug, camizestrant, for people with a common type of early breast cancer. It aims to see if camizestrant, compared to usual hormone therapy, can better prevent the cancer from coming back.

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

This study looks at a drug called abemaciclib, given with standard hormone therapy after surgery for a type of breast cancer. We want to see if it's safe and helps stop the cancer coming back in people with certain high-risk breast cancers.

A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

This study looks at a new combination of medicines for postmenopausal women with a certain type of breast cancer. It tests if abemaciclib with standard hormone therapy works better than hormone therapy alone.

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

This study is looking at a new drug, PF-07220060, combined with letrozole for advanced breast cancer. It compares this new treatment to existing approved therapies to see if it's safe and works well for people whose cancer needs hormones to grow.

A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population

This study looks at new treatments for HR-positive/HER2-negative breast cancer that has been surgically removed. It uses blood tests to find tiny traces of cancer that might come back. If found, patients may get new drug combinations to see if they can stop the cancer from returning.

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

This study looks at new drug combinations for advanced breast cancer. It compares saruparib and camizestrant with common existing treatments to see which works best for people with specific genetic changes (BRCA1, BRCA2, or PALB2m) in their cancer.

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

This study looks at a new drug, abemaciclib, combined with standard treatment for prostate cancer that has spread. We want to see if this combination can stop the cancer from getting worse for longer in men whose cancer is still responding to hormone therapy.

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

This study is looking at new treatments for a specific type of ovarian cancer that has come back or won't go away. We want to see if these treatments are safe and effective for patients whose cancer has certain genetic features.

A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

This study looks at different treatment combinations for advanced breast cancer, including those that have spread or are hard to remove. Doctors want to see how well these new drug combinations work and if they are safe for patients.

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

This study is for people with advanced breast cancer that has a specific genetic change (PIK3CA). It's testing a new drug, Tersolisib, alongside other cancer medicines, to see if it's safe and helps treat the disease effectively.

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

This study looks at a new combination treatment for advanced breast cancer that's hormone-positive and HER2-negative. It combines a new drug called capivasertib with existing treatments to see if it works better at slowing down the cancer's growth.

PreOperative Endocrine Therapy for Individualised Care With Abemaciclib

This study looks at a new way to treat breast cancer in post-menopausal women. It tests if adding a drug called abemaciclib to standard hormone therapy can better stop the cancer from coming back after surgery, especially for those at higher risk.

J6M-MC-JSGD: A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Tersolisib (LY4064809) Combined with a CDK4/6 Inhibitor and Endocrine Therapy in Adults with HR+, HER2- Advanced Breast Cancer with a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)

This study is for adults with advanced breast cancer that is HR+, HER2-, and has a specific gene change (PIK3CA mutation), who haven't had previous treatment for advanced disease. It tests a new drug called tersolisib alongside standard hormone therapy and other targeted drugs to see if it can help stop the cancer from growing.

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

This study is a research programme looking at new ways to treat cancer in children and young adults aged 1 to 39. It tests different medicines to find out how well they work and if they are safe.

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

This study is testing a new drug, AZD9833, for advanced breast cancer. It's for people whose cancer has a specific gene change (ESR1 mutation) and are already on certain treatments. Researchers want to see if adding AZD9833 works better than current medicines.

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer

This study is testing a new drug called elacestrant with other breast cancer medicines. It's for people with a specific type of advanced breast cancer that has spread. The main goals are to see if these drug combinations are safe and if they can help shrink the cancer.